Will joined Insmed in 2012 as President and Chief Executive Officer and as a member of the board of directors. He became Chair of the Board of Directors in November 2018. Will is the former Co-Founder, President, and Chief Financial Officer of Aegerion Pharmaceuticals, Inc. (Nasdaq: AEGR), and previously spent more than 10 years working in investment banking in the U.S. and Europe. He also previously worked for the U.S. government.

Will holds a Bachelor of Arts degree cum laude from Oberlin College as well as a Master of Business Administration and a Juris Doctor with Honors from Case Western Reserve University. Will is the Chair of the board of directors of NewAmsterdam Pharma (Nasdaq: NAMS).

Dr. Tanya Fischer is the Chief Medical Officer at Tenvie Therapeutics, where she is building the company’s development organization and advancing a portfolio of first-in-class therapeutic programs targeting CNS and PNS diseases. Before joining Tenvie, she served as Head of Research and Development and Chief Medical Officer at Zenas Biopharma, leading an integrated pipeline in inflammatory diseases from discovery through late-stage clinical development. Her earlier leadership roles span both biotechnology and large pharmaceutical organizations, including Chief Development Officer and Head of Translational Medicine at Biohaven Pharmaceuticals, Vice President of CNS Development at Alnylam Pharmaceuticals, and Global Project Head at Sanofi across the Multiple Sclerosis, Neurology, and Gene Therapy therapeutic areas.

Dr. Fischer has directed clinical programs from Phase 1 through Phase 4 across a broad range of modalities, including small molecules, biologics, gene therapies, and siRNA therapeutics. Her work contributed to the approval of cladribine (Mavenclad®) for multiple sclerosis and the expansion of Alnylam’s CNS pipeline, including launching a clinical trial allowing for the first-ever administration of siRNA directly into the human brain. At Sanofi, she led global programs for rare genetic and neurodegenerative disorders and launched the first industry-sponsored trials in a genetic form of Parkinson’s disease (GBA-PD) and neuronopathic Gaucher disease.

A neurologist with subspecialty expertise in demyelinating diseases and chronic neuropathic pain, Dr. Fischer completed her residency at Yale New Haven Hospital and later served as Assistant Professor of Neurology at Yale. Her VA-supported research on genetic and acquired pain disorders earned her the Presidential Early Career Award for Scientists and Engineers (PECASE) in 2011. She remains an active contributor to the neuroscience community through advisory roles, including service on scientific boards and international consortia focused on Parkinson’s disease and neurodegeneration.

Fractional CMO and Clinical Strategy Consultant advises to multiple ADC biotechs on discovery and data packages (preclinical and clinical). Designs or refines clinical and regulatory strategies. Engages with boards/investors to explore clinical opportunities, risks, and impact. Serves on scientific advisory boards. Prepares for IND submission and regulatory engagement. Enables comprehensive FIH/Phase 1/2 trial designs, engages top tier investigators/sites, and efficient clinical execution.

Carey is Chief Medical Officer at IntegerBio, a company focused on harnessing the immune system to design broad multiviral therapeutics. He is a physician-scientist with deep experience in the pharmaceutical and biotechnology industry, with a focus on developing novel therapies for serious infectious diseases, including HIV, hepatitis B, hepatitis C, and hepatitis delta. He has contributed to or led the development of several approved treatments, including doravirine (Pifeltro), doravirine/lamivudine/tenofovir disoproxil fumarate (Delstrigo), and fostemsavir (Rukobia) for HIV, as well as asunaprevir (Sunvepra) and daclatasvir (Daklinza) for hepatitis C. 

Carey began his industry career at Bristol Myers Squibb in 2009, where he worked in exploratory clinical and translational research, focusing on early-phase clinical development for HIV and hepatitis C. In 2016, he joined Merck & Co. as Executive Director and Product Development Lead in Global Clinical Development – Infectious Diseases, where he led the worldwide development and approval of two HIV treatments. Most recently, Carey served as Senior Vice President at Vir Biotechnology, where he led the clinical research group and served as Interim Chief Medical Officer in 2024, primarily overseeing programs in hepatitis B, hepatitis delta, and HIV. 

Carey earned his bachelor’s degree in molecular biology from Princeton University and his M.D. and Ph.D. in microbiology and immunology from West Virginia University. He completed his internal medicine residency and infectious diseases fellowship in the Physician-Scientist Training Program at  Vanderbilt University Medical Center.

Dr. Raymond Urbanski is a distinguished physician, scientist, and pharmaceutical executive with over two decades of leadership in the pharmaceutical industry. His career spans numerous therapeutic areas, including oncology, hematology, cardiovascular disease, endocrinology, and neurology. His data-driven approach and commitment to patient-centered innovation have contributed to the development of groundbreaking treatments in solid tumors, hematologic malignancies, rare diseases, and chronic conditions such as diabetes and other metabolic disorders.

As a strategic leader, he has successfully expanded and diversified product pipelines, guided clinical organizations through dynamic industry changes, and optimized development teams for peak performance. His expertise extends to high-level drug development strategies, risk assessment, regulatory filings, and operational efficiency. Throughout his career, he has held executive roles of increasing responsibility, culminating in his tenure as Chief Medical Officer for multiple biotechnology and global pharmaceutical companies.

In addition to his industry leadership, Dr. Urbanski co-founded and served as President of Clinical Studies Associates, a multi-state site management organization. He also served as an Investigator or Medical Director for over 100 clinical trials, contributing to numerous high- impact publications and international conference presentations.

Dr. Urbanski earned his medical degree from the New Jersey Medical School, where he received the Michael W. Pozen Scholarship. He completed his residency and fellowship in the American Board of Internal Medicine’s Clinical Investigator Pathway at Thomas Jefferson University Hospital in Philadelphia. He also holds a Ph.D. in Pharmacology from UMDNJ Graduate School of Biomedical Sciences, where he was awarded the GSBS Fellowship Award.

With an unwavering dedication to medical advancement, Dr. Urbanski continues to shape the future of clinical research and pharmaceutical innovation.

Stéphane Champiat is a Medical Oncologist, and a specialist of early drug development and Immunotherapy.

Dr. Champiat completed his medical school at Paris VI University and completed his medical oncology residency at the University of Nantes in France. He completed a PhD in Immunology from the Paris-Saclay University and worked as a postdoctoral researcher at the University of California San Francisco, focusing on T-cell immunity.

For the last 10 years, Dr. Champiat was working in the early development of cancer therapeutics, in particular novel immunotherapies in the Drug Development Department (DITEP) at the Gustave Roussy Cancer Center in Villejuif, France.

Dr. Champiat has dedicated his clinical practice to innovative cancer care, particularly immunotherapy. He developed the iTOX program to improve management of immune- related adverse events and co-founded the annual iTOX Symposium. His operational development of intratumoral immunotherapy at Gustave Roussy has set a benchmark in the field. An accomplished clinician-investigator, Dr. Champiat has led numerous Phase I trials, advancing checkpoint blockers, T-cell engager immunotherapies and more. Dr. Champiat has co-authored more than 100 scientific publications in peer-reviewed journals such as Nature Reviews Clinical Oncology, Lancet Oncology, Annals of Oncology, Journal of Clinical Oncology and Clinical Cancer Research. In July 2024, Dr. Champiat joined The University of Texas MD Anderson Cancer Center as an Associate Professor in the Department of Investigational Cancer Therapeutics, to transform and lead the development of the next generation of immunotherapies.

Daniel Quirk is the Chief Medical Officer and Head of Medical Affairs at Biogen. Dr. Quirk joined Biogen in October 2024 and is a highly accomplished medical professional with a diverse background in medicine, public health, and business administration.

Prior to joining the Biogen team, Dr. Quirk was Senior Vice President of Worldwide Medical Affairs for Immunology and Neuroscience at Bristol-Myers Squibb (BMS), and previously served as Senior Vice President of US Medical Affairs, and Vice President of US Medical Affairs for Immunology and Fibrosis. Earlier in his career, Dr. Quirk held key leadership positions at Pfizer, with the most recent being Vice President and Medical Category Lead for Inflammation and Immunology in Emerging Markets.

Dr. Quirk enjoyed a successful clinical career before joining industry and served as the Associate Chief of Gastroenterology at Thomas Jefferson University Health Systems in Philadelphia, where he contributed significantly to patient care, clinical research, and medical education.

Dr. Quirk earned his MD from Brown University, followed by an MPH from the Harvard School of Public Health and an MBA from The Wharton School at the University of Pennsylvania. Dr. Quirk completed his medical training at the Johns Hopkins Hospital and the Massachusetts General Hospital.

Jim has over 20 years of experience managing product development and commercialization of medical devices, advanced coatings, and drug delivery technologies.  He has worked with both industry and academic partners, guiding products through all stages of development from conceptualization through to customer release.   At ProMed Pharma, he oversees program development activities for polymer-based drug releasing implants and combination device components, working with a team of engineers to develop new drug delivery vehicles as well as robust manufacturing processes and platforms for controlled release of drugs from a variety of materials for applications in cardiovascular, women’s health, and ophthalmology.  He has a Ph.D. in Applied Physics from Vanderbilt University and an M.S. in Management of Technology from the University of Texas-San Antonio.

• Accomplished physician-scientist and biopharmaceutical executive with over two decades of experience in oncology drug development, clinical strategy, and organizational leadership with a strong academic foundation and objective track record of success at companies including Exelixis, CytomX, BeiGene (now BeOne), Medivation, and Genentech.
• Accountable for building and leading global oncology development organizations, managing billion-dollar budgets, and creating and executing on strategic initiatives across early and late- stage oncology pipelines.
• Successful execution of numerous global clinical trials and regulatory submissions resulting in product launches of cabozantinib, Zanubrutinib, tislelizumab, enzalutamide, talazoparib, atezolizumab, bevacizumab and cobimetinib.
• Recognized for visionary cross functional leadership and effective organizational development, creating scalable drug development infrastructures and implementing right-sized decision-making framework.
• Credible and effective communicator to internal organization, executives, board members, analysts, investor, partners and regulators.
• Expert in modality and indication agnostic oncology drug development.

Shaheen Lakhan, MD, PhD, FAAN, is a physician scientist, biotech executive, and founder of Boricua Bio. He is board certified in neurology and pain medicine and trained at the Cleveland Clinic and Massachusetts General Hospital. Across more than two decades in academic medicine and industry, he has led the discovery, clinical development, and commercialization of innovative therapeutics spanning digital medicine, CNS disorders, immunology, and oncology.

Dr. Lakhan most recently served as Chief Medical and Scientific Officer at Click Therapeutics, where he advanced multiple digital medicines from concept through pivotal trials, regulatory interactions, FDA approvals, and commercial launch planning. He has designed multinational clinical programs, executed major strategic partnerships with global pharmaceutical companies, and built high performing medical, clinical, and regulatory organizations in high growth environments.

A prolific scholar with more than 100 peer reviewed publications, Dr. Lakhan has developed foundational frameworks in digital medicine, closed loop therapeutics, and payer adoption strategies. His work has been featured in leading scientific journals and major media outlets. He is a US Presidential and Congressional awardee and serves as professor at Morehouse School of Medicine, Western University of Health Sciences, and A.T. Still University. He also advises companies and boards on therapeutic strategy, AI enabled clinical development, and next generation neurotechnology.

Dr. Lakhan is committed to expanding therapeutic access and advancing science that meaningfully improves patient lives. At Boricua Bio, he integrates global expertise with island based innovation to accelerate the future of novel medicine.